Hubbry Logo
Magnesium deficiencyMagnesium deficiencyMain
Open search
Magnesium deficiency
Community hub
Magnesium deficiency
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Magnesium deficiency
Magnesium deficiency
Magnesium deficiency
View on Wikipedia
from Wikipedia

Magnesium deficiency
Other namesHypomagnesia, hypomagnesemia
Magnesium
SpecialtyEndocrinology
SymptomsTremor, poor coordination, nystagmus, seizures[1]
ComplicationsSeizures, cardiac arrest (torsade de pointes), low potassium[1]
CausesAlcoholism, starvation, diarrhea, increased urinary loss, poor absorption from the intestines, certain medications[1][2]
Diagnostic methodBlood levels < 0.6 mmol/L (1.46 mg/dL)[1]
TreatmentMagnesium salts[2]
FrequencyRelatively common (hospitalized people)[2]

Magnesium deficiency is an electrolyte disturbance in which there is a low level of magnesium in the body.[3] Symptoms include tremor, poor coordination, muscle spasms, loss of appetite, personality changes, and nystagmus.[1][2] Complications may include seizures or cardiac arrest such as from torsade de pointes.[1] Those with low magnesium often have low potassium.[1]

Causes include low dietary intake, alcoholism, diarrhea, increased urinary loss, and poor absorption from the intestines.[1][4][5] Some medications may also cause low magnesium, including proton pump inhibitors (PPIs) and furosemide.[2] The diagnosis is typically based on finding low blood magnesium levels, also called hypomagnesemia.[6] Normal magnesium levels are between 0.6 and 1.1 mmol/L (1.46–2.68 mg/dL) with levels less than 0.6 mmol/L (1.46 mg/dL) defining hypomagnesemia.[1] Specific electrocardiogram (ECG) changes may be seen.[1]

Treatment is with magnesium either by mouth or intravenously.[2] For those with severe symptoms, intravenous magnesium sulfate may be used.[1] Associated low potassium or low calcium should also be treated.[2] The condition is relatively common among people in hospitals.[2]

Signs and symptoms

[edit]

Deficiency of magnesium can cause tiredness, generalized weakness, muscle cramps, abnormal heart rhythms, increased irritability of the nervous system with tremors, paresthesias, palpitations, low potassium levels in the blood, hypoparathyroidism which might result in low calcium levels in the blood, chondrocalcinosis, spasticity and tetany, migraines, epileptic seizures,[7] basal ganglia calcifications[8] and in extreme and prolonged cases coma, intellectual disability or death.[9] Magnesium deficiency is strongly associated with and appears to contribute to obesity, insulin resistance, metabolic syndrome, and type 2 diabetes, although the causal mechanism is not fully understood.[10][4][5]

Causes

[edit]

Magnesium deficiency may result from gastrointestinal or kidney causes. Gastrointestinal causes include low dietary magnesium intake, reduced gastrointestinal absorption, or increased gastrointestinal loss due to rapid gastrointestinal transits. Kidney causes involve increased excretion of magnesium. Poor dietary intake of magnesium has become an increasingly important factor: many people consume diets high in refined foods such as white bread and polished rice, which have been stripped of magnesium-rich plant fiber.[11]

Magnesium deficiency is common in hospitalized patients. Up to 12% of all people admitted to hospital, and as high as 60–65% of people in an intensive care unit (ICU), have hypomagnesemia.[12]

About 57% of the US population does not meet the US RDA for dietary magnesium intake.[13] Kidneys are very efficient at maintaining body levels; however, if the diet is deficient, or certain medications such as diuretics or proton pump inhibitors are used,[14] or in chronic alcoholism,[15] levels may drop.

Deficiencies may be due to the following conditions:

Medications

[edit]

Genetics

[edit]

Metabolic abnormalities

[edit]

Other

[edit]
  • Chronic alcoholism: Alcohol intake leads to enhanced diuresis of electrolytes, possibly due to alcohol-induced kidney tubular cell damage.[25] Hypomagnesemia is also thought to occur due to reduced magnesium intake due to malnutrition and increased gastrointestinal losses.[25][26][27][28][29] Hypomagnesemia is the most common electrolyte abnormality in those with chronic alcoholism.[25] Chronic hypomagnesemia in those with chronic alcoholism is associated with liver disease and a worse prognosis,[25]
  • Acute myocardial infarction: Within the first 48 hours after a heart attack, 80% of patients have hypomagnesemia. This could be the result of an intracellular shift because of an increase in catecholamines,
  • Malabsorption,
  • Acute pancreatitis,
  • Fluoride poisoning,
  • Massive transfusion (MT) is a lifesaving treatment of hemorrhagic shock, but can be associated with significant complications.[30]

Pathophysiology

[edit]

Magnesium is ubiquitous in the human body as well as being present in all living organisms and the ion is a known co-factor in over 300 known enzymatic reactions including DNA and RNA replication, protein synthesis, acting as an essential co-factor of ATP during its phosphorylation via ATPase. It is also extensively involved in intracellular signalling.[20][25] It is involved in protein synthesis, regulating glucose, lipid and protein metabolism, muscle and nerve functioning, vascular tone (affecting blood vessel contraction, thus helping to regulate blood pressure), bone development, energy production, the maintenance of normal heart rhythm, and the regulation of glucose, among other important roles.[15][25] Physiologically, it acts as a calcium antagonist.[25] Thus, the effects of low magnesium are widespread. Low magnesium intake over time can increase the risk of illnesses, including high blood pressure and heart disease, diabetes mellitus type 2, osteoporosis, and migraines.[15]

Magnesium has several effects:

Potassium

[edit]

Low potassium levels are usually associated with hypomagnesemia. Low magnesium levels act to inhibit the sodium-potassium pump (Na-K-ATPase) which normally pumps sodium to the extracellular space and potassium into the intracellular space, using ATP as energy to pump both cations against their concentration gradient, to maintain relatively high levels of potassium in the intracellular compartment and high levels of sodium in the extracellular space.[25] Hypomagnesemia also causes activation of the Renal outer medullary potassium channel (ROMK), a potassium channel that causes potassium losses in the urine via the cortical collecting duct in the kidney.[25] And hypomagnesemia prevents low potassium levels from activating the sodium-chloride cotransporter (NCC) and downregulates NCC levels, which prevents sodium and chloride reabsorption from the kidney tubule.[25] The inhibition of the sodium-potassium pump results in more potassium remaining in the extracellular space (interstitial fluid and plasma). This potassium is then lost as blood is filtered in the kidney as ROMK channel activation causes potassium losses in the cortical collecting duct and NCC inhibition causes decreased sodium-chloride reabsorption by kidney tubules, with subsequent increased sodium-chloride (and water) delivery to the distal tubule, and associated diuresis and kaliuresis (kidney potassium loss in the urine).[25] Overall, the net effect of low magnesium levels in the body is renal potassium losses (in the urine); thus, clinically, low potassium levels are often refractory to supplementation without also correcting low magnesium levels.[25][31]

Patients with diabetic ketoacidosis should have their magnesium levels monitored to ensure that the serum loss of potassium, which is driven intracellularly by insulin administration, is not exacerbated by additional urinary losses. [citation needed]

Calcium

[edit]

Release of calcium from the sarcoplasmic reticulum is inhibited by magnesium. Thus, hypomagnesemia results in an increased intracellular calcium level. This inhibits the release of parathyroid hormone, which can result in hypoparathyroidism and hypocalcemia. Furthermore, it makes skeletal and muscle receptors less sensitive to parathyroid hormone.[12]

Arrhythmia

[edit]

Magnesium is needed for the adequate function of the Na+/K+-ATPase pumps in cardiac myocytes, the muscles cells of the heart. A lack of magnesium inhibits the reuptake of potassium, causing a decrease in intracellular potassium. This decrease in intracellular potassium results in tachycardia.[citation needed]

Pre-eclampsia

[edit]

Magnesium has an indirect antithrombotic effect on platelets and endothelial function. Magnesium increases prostaglandins, decreases thromboxane, and decreases angiotensin II, microvascular leakage, and vasospasm through its function similar to calcium channel blockers.[citation needed] Convulsions are the result of cerebral vasospasm. The vasodilatory effect of magnesium seems to be the major mechanism.

Asthma

[edit]

Magnesium exerts a bronchodilatatory effect, probably by antagonizing calcium-mediated bronchoconstriction.[32]

Neurological effects

[edit]

Diabetes mellitus

[edit]

Magnesium deficiency is frequently observed in people with type 2 diabetes mellitus, with an estimated prevalence ranging between 11 and 48%.[34] Magnesium deficiency is strongly associated with high glucose and insulin resistance, which indicate that it is common in poorly controlled diabetes.[35] Patients with type 2 diabetes and a magnesium deficiency have a higher risk of heart failure, atrial fibrillation, and microvascular complications.[36] Oral magnesium supplements has been demonstrated to improve insulin sensitivity and lipid profile.[37][38][39] A 2016 meta-analysis not restricted to diabetic subjects found that increasing dietary magnesium intake, while associated with a reduced risk of stroke, heart failure, diabetes, and all-cause mortality, was not clearly associated with lower risk of coronary heart disease (CHD) or total cardiovascular disease (CVD).[40]

Homeostasis

[edit]

Magnesium-rich foods include cereals, green vegetables (with magnesium being a main component of chlorophyll), beans, and nuts.[25] It is absorbed primarily in the small intestine via paracellular transport; passing between intestinal cells. Magnesium absorption in the large intestine is mediated by the transporters TRPM6 and TRPM7.[25]

The body contains about 25 grams of magnesium.[25] Of the body's magnesium, 50-60% is stored in bone, with the remainder, about 40-50%, being stored in muscle or soft tissue, with about 1% being in the plasma.[41] Therefore, normal plasma levels of magnesium may sometimes be seen despite a person being in a state of magnesium deficiency and plasma magnesium levels may underestimate the level of deficiency. Plasma magnesium levels may more accurately reflect magnesium stores when consideration is also given to urinary magnesium losses and oral magnesium intake.[25]

Inside cells, 90-95% of magnesium is bound to ligands, including ATP, ADP, citrate, other proteins, and nucleic acids.[25] In the plasma, 30% of magnesium is bound to proteins via free fatty acids; therefore, elevated levels of free fatty acids are associated with hypomagnesemia and a possible risk of cardiovascular disease.[25]

The kidneys regulate magnesium levels by reabsorbing magnesium from the tubules. In the proximal tubule (at the beginning of the nephron, the functional unit of the kidney) 20% of magnesium is reabsorbed via paracellular transport with claudin 2 and claudin 12 forming channels to allow for reabsorption.[25] 70% of magnesium is reabsorbed in the thick ascending limb of the loop of Henle where claudins 16 and 19 form the channels to allow for reabsorption.[25] In the distal convoluted tubule, 5-10% of magnesium is reabsorbed transcellularly (through the cells) via the transporters TRPM6 and TRPM7. Epidermal growth factor and insulin activate TRPM6 and 7 and increase magnesium levels via increased renal reabsorption.[25]

Diagnosis

[edit]

Magnesium deficiency or depletion is a low total body level of magnesium; it is not easy to measure directly.[42]

Blood magnesium

[edit]

Typically the diagnosis is based on finding hypomagnesemia, a low blood magnesium level,[43] which often reflects low body magnesium;[6] however, magnesium deficiency can be present without hypomagnesemia, and vice versa.[42] A plasma magnesium concentration of less than 0.6 mmol/L (1.46 mg/dL) is considered to be hypomagnesemia;[1] severe disease generally has a level of less than 0.5 mmol/L (1.25 mg/dL).[2]

Electrocardiogram

[edit]

The electrocardiogram (ECG) change may show a tachycardia with a prolonged QT interval.[44] Other changes may include prolonged PR interval, ST segment depression, flipped T waves, and long QRS duration.[1]

Treatments

[edit]
Main article: Magnesium (medical use)

Treatment of magnesium deficiency depends on the degree of deficiency and the clinical effects. Replacement by mouth is appropriate for people with mild symptoms, while intravenous replacement is recommended for people with severe symptoms.[45]

Numerous oral magnesium preparations are available. In two trials of magnesium oxide, one of the most common forms in magnesium dietary supplements because of its high magnesium content per weight, was less bioavailable than magnesium citrate, chloride, lactate, or aspartate.[46][47] Amino-acid chelate was also less bioavailable.[48]

Intravenous magnesium sulfate (MgSO4) can be given in response to heart arrhythmias to correct for hypokalemia, preventing pre-eclampsia, and has been suggested as having potential use in asthma.[1]

Food

[edit]

Food sources of magnesium include leafy green vegetables, beans, nuts, and seeds.[49]

Epidemiology

[edit]

Hypomagnesemia may be seen in 3-10% of the general population.[25] It is present in an estimated 10-30% of people with diabetes, 10-60% of hospitalized people and greater than 65% of people in the ICU.[25][2] In hospitalized patients, hypomagnesemia is associated with an increased length of stay. And in those in an ICU, it is associated with a higher risk of requiring mechanical ventilation, and death.[50][51] In population-based cohort studies, chronic magnesium deficiency was associated with an increased risk of cardiovascular death and overall death.[25][52]

History

[edit]

Magnesium deficiency in humans was first described in the medical literature in 1934.[53]

Plants

[edit]
A plant with magnesium deficiency

Magnesium deficiency is a detrimental plant disorder that usually occurs in strongly acidic, light, sandy soils, where magnesium can be easily leached away. Magnesium is an essential macronutrient constituting 0.2-0.4% of plants' dry matter, and is necessary for normal plant growth.[54] Excess potassium, generally due to fertilizers, further aggravates the stress from magnesium deficiency,[55] as does aluminium toxicity.[56]

Magnesium has an important role in photosynthesis because it forms the central atom of chlorophyll.[54] Therefore, without sufficient amounts of magnesium, plants begin to degrade the chlorophyll in the old leaves. This causes the main symptom of magnesium deficiency, interveinal chlorosis, or yellowing between leaf veins, which stay green, giving the leaves a marbled appearance. Due to magnesium's mobile nature, the plant will first break down chlorophyll in older leaves and transport the Mg to younger leaves, which have greater photosynthetic needs. Therefore, the first sign of magnesium deficiency is the chlorosis of old leaves, which progresses to the young leaves as the deficiency progresses.[57] Magnesium also acts as an activator for many critical enzymes, including ribulosebisphosphate carboxylase (RuBisCO) and phosphoenolpyruvate carboxylase (PEPC), both essential enzymes in carbon fixation. Thus, low amounts of Mg decrease photosynthetic and enzymatic activity within the plants. Magnesium is also crucial in stabilizing ribosome structures; hence, a lack of magnesium causes depolymerization of ribosomes, leading to premature aging of the plant.[54] After prolonged magnesium deficiency, necrosis and dropping of older leaves occurs. Plants deficient in magnesium also produce smaller, woodier fruits.

Magnesium deficiency in plants may be confused with zinc or chlorine deficiencies, viruses, or natural aging, since all have similar symptoms. Adding Epsom salts (as a solution of 25 grams per liter or 4 oz per gal) or crushed dolomitic limestone to the soil can rectify magnesium deficiencies. An organic treatment is to apply compost mulch, which can prevent leaching during excessive rainfall and provide plants with sufficient amounts of nutrients, including magnesium.[58]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Magnesium deficiency

View on Grokipedia
from Grokipedia
Magnesium deficiency, medically termed hypomagnesemia, is an characterized by abnormally low levels of magnesium in the blood, typically below 0.75 mmol/L (or 1.8 mg/dL). This essential mineral plays critical roles in over 300 enzymatic reactions, including muscle and nerve function, energy production, protein synthesis, and regulation. Deficiency can arise from insufficient dietary intake, increased gastrointestinal or renal losses, or redistribution within the body, with a of 2.5–15% in the general and 12–20% among hospitalized patients, and higher rates in at-risk groups. Common causes of magnesium deficiency include chronic alcoholism, which promotes renal magnesium wasting and poor nutrition; gastrointestinal disorders such as or chronic that impair absorption; and conditions like , where and lead to excessive urinary . Certain medications, including inhibitors, diuretics, and antibiotics, can also deplete magnesium by interfering with absorption or increasing . , older age, and excessive sweating or burns further contribute to depletion, while as of 2016, about 48% of U.S. adults (with recent estimates around 50%) consume less than the estimated average requirement for magnesium from diet alone, heightening subclinical deficiency risk. Symptoms of magnesium deficiency often manifest gradually and may include , loss of appetite, , , muscle cramps such as leg cramps after exercise (due to impaired muscle relaxation), and tremors in early stages. Magnesium deficiency is strongly linked to muscle cramps and can contribute to fatigue and mental symptoms such as anxiety or depression (which may relate to brain fog). As deficiency worsens, it can lead to numbness, tingling, seizures, personality changes, and severe cardiac arrhythmias due to magnesium's role in stabilizing cardiac membranes and electrolyte balance. Evidence directly linking magnesium deficiency to cold hands and feet is limited, though some sources suggest it may affect circulation due to magnesium's role in vascular function. Associated complications include and , which exacerbate neuromuscular irritability and increase risks of , , and . In severe cases, particularly in intensive care patients, hypomagnesemia correlates with higher mortality rates from ventricular arrhythmias and other cardiovascular events. Diagnosis primarily involves measuring serum magnesium levels, though this may not reflect total body stores; additional tests like 24-hour urinary magnesium or the magnesium-loading test can assess intracellular deficits, with emerging tools such as the magnesium depletion score (as of 2025) helping identify subclinical risks. Treatment focuses on correcting the underlying cause and replenishing magnesium through oral supplements (e.g., magnesium oxide or citrate) for mild cases or intravenous administration for acute hypomagnesemia, with monitoring to avoid hypermagnesemia. Prevention emphasizes a balanced diet rich in magnesium sources like leafy greens, nuts, seeds, and whole grains, alongside managing risk factors such as alcohol use and medication effects.

Overview

Definition

Magnesium deficiency, also known as hypomagnesemia, is a condition characterized by insufficient magnesium levels in the body to support normal physiological functions, typically indicated by a total body magnesium deficit or reduced serum concentrations. This arises when magnesium intake, absorption, or retention fails to meet the body's requirements, leading to disruptions in cellular processes that rely on magnesium as a cofactor. The term "hypomagnesemia" derives from the Greek prefix "hypo-" meaning under or below, combined with "magnesemia," referring to magnesium in the , first documented in in 1933. Serum magnesium levels are the primary clinical measure for assessing this deficiency, expressed in units such as milligrams per deciliter (mg/dL) or millimoles per liter (mmol/L). Normal serum magnesium concentrations generally range from 1.8 to 2.3 mg/dL (equivalent to 0.75 to 0.95 mmol/L), with hypomagnesemia defined as levels below 0.75 mmol/L (approximately 1.8 mg/dL). These ranges can vary slightly between laboratories due to differences in measurement techniques, but they provide a standard benchmark for evaluation. While hypomagnesemia specifically denotes low extracellular (serum) magnesium, true magnesium deficiency encompasses broader intracellular depletion, where tissue magnesium stores are diminished even in the presence of normal serum levels. This distinction is critical because serum magnesium represents only about 1% of total body magnesium, and intracellular deficits can occur without altering blood concentrations, potentially leading to subclinical deficiency. Such cellular-level shortages impair magnesium's role in over 300 enzymatic reactions, underscoring the need for comprehensive assessment beyond serum alone.

Physiological role

Magnesium is an essential that functions as a cofactor for over 300 enzymes involved in critical biochemical processes, including the synthesis of (ATP) through and , as well as DNA and RNA transcription and protein synthesis. This enzymatic role underscores magnesium's importance in energy metabolism and cellular maintenance, where it stabilizes nucleotide complexes and facilitates phosphate transfer reactions necessary for these pathways. In neuromuscular function, magnesium plays a key role in nerve impulse conduction, release, and by acting as a natural and promoting calcium re-uptake into the . It also supports balance through interactions with sodium (Na⁺), (K⁺), and calcium (Ca²⁺) ions, serving as a cofactor for the Na⁺-K⁺- pump and helping maintain stable intracellular and extracellular concentrations of these s. Structurally, approximately 50% to 60% of the body's total magnesium content—about 25 grams in adults—is stored in bones, where it contributes to formation and serves as a for systemic . The recommended dietary allowance (RDA) for magnesium in adults is 310–320 mg per day for women and 400–420 mg per day for men, with primary dietary sources including nuts (such as almonds), green leafy vegetables (like ), and whole grains. Absorption occurs predominantly in the through both paracellular passive and transcellular mediated by the transient receptor potential melastatin 6 (TRPM6) channel on the apical membrane of enterocytes. This dual mechanism allows for efficient uptake, with varying based on dietary factors and individual needs.

Causes

Gastrointestinal and dietary factors

Inadequate dietary intake of magnesium is a primary contributor to deficiency, particularly in populations relying on processed foods, which often lack magnesium-rich whole grains, nuts, seeds, and leafy greens. Diets that rely heavily on foods relatively low in magnesium—such as beef (approximately 20 mg per 3-ounce serving), cooked white rice (approximately 10 mg per ½-cup serving), and cheese (typically low, varying by type but often around 20-40 mg per serving)—while lacking sufficient high-magnesium plant-based sources like spinach (78 mg per ½ cup boiled), almonds (80 mg per ounce), and pumpkin seeds (156 mg per ounce), can contribute to inadequate intake. This issue is exacerbated in cases of or , where poor nutritional choices lead to chronically low consumption; for instance, long-term excessive alcohol intake is associated with diets deficient in magnesium due to overall caloric and neglect. In Western diets, average daily magnesium intake from food sources is approximately 234 mg for women and 268 mg for men, falling below the Recommended Dietary Allowance (RDA) of 310–320 mg for women and 400–420 mg for men aged 31–50 years. Malabsorption syndromes significantly impair magnesium uptake in the , where approximately 30%–40% of dietary magnesium is normally absorbed, primarily in the . Conditions such as celiac disease, , and regional disrupt this process through chronic inflammation and damage to the absorptive mucosa, leading to and reduced . Chronic from these or other causes further limits absorption by accelerating transit time and increasing fecal losses. , including procedures like gastric bypass or , reduces the functional surface area of the , particularly the , resulting in postoperative magnesium deficiency. Gastrointestinal losses beyond contribute to deficiency through mechanisms that increase fecal or luminal of magnesium. Prolonged or nasogastric suction removes unabsorbed magnesium from the upper gut, while abuse promotes rapid colonic transit and elevated fecal output. Under normal conditions, fecal magnesium is about 100–150 mg per day, representing unabsorbed dietary magnesium; however, these interventions can substantially exceed this baseline, tipping the balance toward depletion. Certain dietary components can inhibit magnesium absorption by forming insoluble complexes or competing for uptake sites in the intestine. High-phytate foods, such as whole grains and , bind magnesium via , reducing in a dose-dependent manner. Oxalates in foods like chelate magnesium, further lowering absorption compared to low-oxalate alternatives like . Additionally, high-fiber diets containing partly fermentable fibers (e.g., ) or non-fermentable fibers (e.g., ) increase fecal bulk and excretion, thereby decreasing net magnesium uptake.

Renal and metabolic disorders

Renal magnesium handling involves the reabsorption of approximately 95% of filtered magnesium, primarily through paracellular pathways in the and thick ascending limb of the , with the remaining 5-10% undergoing active transcellular reabsorption in the via the TRPM6 channel. The fractional excretion of magnesium (FEMg) is calculated as: FEMg=(UMg×PCrPMg×UCr)×100\text{FEMg} = \left( \frac{U_{\text{Mg}} \times P_{\text{Cr}}}{P_{\text{Mg}} \times U_{\text{Cr}}} \right) \times 100 where UMgU_{\text{Mg}} is urinary magnesium concentration, PMgP_{\text{Mg}} is plasma magnesium concentration, PCrP_{\text{Cr}} is plasma creatinine concentration, and UCrU_{\text{Cr}} is urinary creatinine concentration; normal values are less than 2%, with elevated levels indicating renal wasting. Excessive renal magnesium wasting contributes to hypomagnesemia in various conditions that impair tubular . Hypercalcemia promotes magnesium excretion by competing for in the thick ascending limb, leading to increased urinary losses. Similarly, enhances distal sodium delivery and volume contraction, which can result in secondary hypomagnesemia through augmented renal magnesium excretion. , such as , inhibit the Na-K-2Cl cotransporter in the thick ascending limb, reducing the paracellular driving force for magnesium . Chronic high dietary sodium intake can increase urinary magnesium excretion, potentially reducing overall magnesium levels over time and contributing to higher blood pressure, though acute high-sodium meals have negligible effects. Metabolic disorders also drive magnesium depletion via renal mechanisms. In diabetes mellitus, uncontrolled induces osmotic , which elevates glomerular and impairs tubular reabsorption, resulting in significant magnesium wasting. Proteinuric renal conditions, such as chronic kidney disease (CKD) and diabetic nephropathy, frequently result in renal magnesium wasting due to tubular injury induced by proteinuria, thereby contributing to hypomagnesemia. Magnesium deficiency does not directly cause proteinuria; however, low magnesium levels are associated with more severe proteinuria, and clinical studies have demonstrated that magnesium supplementation can reduce proteinuria levels in patients with diabetic nephropathy. These findings suggest a potential bidirectional relationship or vicious cycle in which hypomagnesemia may exacerbate proteinuria. Post-parathyroidectomy, hungry bone syndrome arises from rapid bone remineralization following suppression, consuming serum magnesium and often necessitating supplementation to correct associated hypomagnesemia. Chronic , particularly with hepatic dysfunction, disrupts renal magnesium handling through altered tubular function and increased urinary excretion, exacerbating deficiency in affected individuals. Inherited tubular disorders frequently manifest as chronic hypomagnesemia due to specific defects in ion transport. , caused by mutations affecting the channel or other components in the thick ascending limb, leads to salt wasting and secondary magnesium loss through disrupted paracellular reabsorption. , resulting from defective NCC (Na-Cl cotransporter) in the , similarly causes hypomagnesemia by impairing magnesium reabsorption alongside and . These conditions highlight the critical role of renal tubular integrity in maintaining magnesium .

Medications and iatrogenic causes

Certain medications can precipitate magnesium deficiency by interfering with renal reabsorption or intestinal absorption of magnesium. diuretics, such as hydrochlorothiazide, and , such as (Lasix), commonly used for and , inhibit magnesium reabsorption in the and thick ascending limb of the , respectively, leading to increased urinary magnesium excretion. Some diuretics, including loop and thiazide types, thereby increase magnesium loss in urine, potentially leading to deficiency, whereas potassium-sparing diuretics may preserve or raise magnesium levels. , such as , can elevate magnesium excretion to up to 240% of baseline levels in experimental models, contributing significantly to hypomagnesemia in chronic users. diuretics similarly enhance magnesium wasting, often resulting in mild to moderate hypomagnesemia, particularly when combined with low dietary intake. Proton pump inhibitors (PPIs), such as omeprazole and , are associated with hypomagnesemia during long-term use exceeding one year, primarily through downregulation of transient receptor potential melastatin 6 and 7 (TRPM6/7) channels in the intestine, impairing active magnesium absorption. The incidence of hypomagnesemia in chronic PPI users is estimated at 10-20%, with higher risks in those on high doses or concurrent diuretics. In 2011, the U.S. issued a safety warning highlighting severe, potentially life-threatening hypomagnesemia cases linked to prolonged PPI therapy, often requiring hospitalization for magnesium replacement. Other pharmaceuticals, including antibiotics (e.g., gentamicin), cause renal that disrupts proximal tubular magnesium , leading to wasting. , a chemotherapeutic agent, induces tubular damage and magnesium depletion through similar nephrotoxic mechanisms, often necessitating supplementation during treatment. inhibitors like cyclosporine impair renal magnesium handling via effects on distal tubular transport, while promotes hypomagnesemia through renal and tubular injury. Iatrogenic causes also encompass procedural interventions, such as total (TPN) formulated without adequate magnesium supplementation, which can rapidly deplete stores due to increased urinary losses in critically ill patients. Additionally, excessive intravenous therapy may precipitate hypomagnesemia by forming insoluble magnesium- complexes, reducing serum availability.

Genetic and congenital factors

Genetic and congenital factors contributing to magnesium deficiency primarily involve inherited disorders known as primary hypomagnesemias, which result from mutations in genes critical for in the kidneys and intestines. These conditions lead to excessive renal magnesium wasting or impaired intestinal absorption, often presenting in infancy or with severe hypomagnesemia that requires lifelong supplementation. Unlike acquired forms, these genetic etiologies are irreversible and stem from monogenic defects, predominantly following autosomal recessive patterns. One of the most characterized primary hypomagnesemias is familial hypomagnesemia with and (FHHNC), caused by biallelic mutations in the CLDN16 or CLDN19 genes, which encode tight-junction proteins claudin-16 and claudin-19, respectively. These mutations disrupt paracellular reabsorption of magnesium and calcium in the thick ascending limb of the , leading to hypomagnesemia, , and progressive that often culminates in renal failure by adolescence or early adulthood. CLDN16 mutations account for approximately 70-80% of cases, while CLDN19 mutations are associated with additional extrarenal features such as ocular abnormalities, including macular and . The disorder is extremely rare, with a of less than 1 in 1,000,000 individuals. Gitelman syndrome represents another key genetic cause, resulting from homozygous or compound heterozygous mutations in the SLC12A3 gene, which encodes the thiazide-sensitive sodium- cotransporter (NCCT) in the . This defect impairs sodium and reabsorption, secondarily causing renal wasting of magnesium and potassium, manifesting as hypokalemic with hypomagnesemia. Symptoms typically emerge in late childhood or adolescence, including muscle cramps, fatigue, and , though some cases remain until adulthood. is the most common inherited tubulopathy, with an estimated prevalence of 1 in 40,000 individuals, particularly among Caucasians. Additional rare syndromes include TRPM6-related hypomagnesemia, also known as hypomagnesemia with secondary (HOMG1), due to mutations in the TRPM6 gene encoding a magnesium-permeable expressed in the and . These mutations abolish TRPM6 channel function, severely impairing active transcellular magnesium absorption in both the gut and , often leading to life-threatening and seizures in neonates. Similarly, EAST/SeSAME syndrome arises from biallelic mutations in the KCNJ10 gene, which encodes the Kir4.1 in the basolateral membrane of renal tubular cells and glial cells; this disrupts potassium recycling and indirectly promotes magnesium wasting, alongside neurological features like , , and sensorineural . Both conditions are autosomal recessive and exceptionally rare, with prevalences below 1 in 1,000,000. Genome-wide association studies (GWAS) have further elucidated common genetic variants influencing magnesium , particularly in genes like CNNM2 and CNNM4, which encode ancient domain-containing proteins involved in renal magnesium efflux. Variants in CNNM2, located on chromosome 10, have been linked to altered serum magnesium levels and dominant forms of hypomagnesemia with and seizures, while CNNM4 variants affect intestinal magnesium absorption. Post-2020 research has identified novel pathogenic variants in these genes, reinforcing their role in magnesium transport and highlighting potential modifiers of deficiency risk in the general population. More recent studies, including a 2023 GWAS identifying SLC41A1 as a key locus for serum magnesium and 2025 reports of novel CNNM2 variants associated with neurodevelopmental disorders, continue to uncover genetic modifiers of magnesium .

Pathophysiology

Electrolyte interactions

Magnesium deficiency profoundly disrupts homeostasis, particularly with , calcium, and sodium, by altering renal handling, hormonal regulation, and cellular transport mechanisms. These interactions often result in concurrent deficiencies that exacerbate the clinical impact of hypomagnesemia, requiring targeted repletion to restore balance. A key interaction involves , where magnesium deficiency impairs the function of the Na⁺-K⁺- pump, which relies on intracellular magnesium as a cofactor for activity. This impairment leads to increased renal wasting, often manifesting as refractory that does not respond adequately to supplementation alone. Correction of in such cases necessitates prior or concomitant magnesium repletion to restore pump function and prevent ongoing loss. Additionally, reduced intracellular magnesium releases its inhibitory effect on renal outer medullary () channels, further promoting kaliuresis and aggravating . Magnesium deficiency also induces through impaired (PTH) secretion and end-organ resistance to PTH action. Magnesium plays a critical role in G-protein coupling within parathyroid cells, and its depletion blocks PTH release in response to low calcium levels, creating a paradoxical inhibition despite . This mechanism indirectly affects ionized calcium regulation by disrupting PTH-mediated calcium mobilization from and renal reabsorption, often requiring magnesium correction to normalize PTH dynamics and resolve . Hyponatremia can arise in magnesium deficiency, particularly in renal wasting scenarios, where associated sodium losses occur alongside magnesium depletion. This is mediated through effects on , as volume contraction from renal wasting stimulates secondary , which may initially promote sodium retention but can contribute to if wasting predominates or in conditions like use. Clinical observations, such as in cases of severe hypomagnesemia with , highlight this association, underscoring the need to address magnesium status in managing hyponatremic states. Magnesium and calcium exhibit interdependence at the cellular level, with magnesium acting as a physiological by blocking voltage-gated calcium channels and limiting calcium influx into cells. In magnesium deficiency, this antagonism is lost, leading to unopposed calcium entry, heightened neuronal and muscular excitability, and manifestations like due to secondary and direct effects on membrane stability, as well as muscle cramps resulting from impaired muscle relaxation. These shifts reflect broader cellular disruptions, such as altered function, but are distinct from enzymatic deficiencies. Intracellular magnesium depletion, a hallmark of deficiency, can be estimated clinically through (RBC) magnesium levels, which better reflect tissue stores than serum measurements. Normal RBC magnesium concentrations range from 4.2 to 6.8 mg/dL (1.7 to 2.8 mmol/L), with values below this indicating significant intracellular deficits that correlate with imbalances.

Cellular and molecular mechanisms

Magnesium serves as a critical cofactor in the formation of the Mg-ATP complex, which is the active substrate for numerous ATP-dependent enzymes involved in cellular energy metabolism. In magnesium deficiency, the availability of this complex diminishes, impairing the function of key enzymes in , such as and , and in within mitochondria, leading to reduced ATP production and overall disruption. This energetic shortfall exacerbates cellular stress, as ATP is essential for maintaining gradients, protein synthesis, and other vital processes. Magnesium deficiency promotes by elevating (ROS) production while diminishing the activity of antioxidant defense systems. Low intracellular magnesium levels are associated with decreased activity of enzymes like (SOD) and , resulting in unchecked ROS accumulation from mitochondrial leaks. This imbalance heightens and protein oxidation, further compromising cellular integrity. At the molecular level, magnesium deficiency triggers inflammatory signaling through upregulation of the pathway, a key that drives the expression of pro-inflammatory genes. Reduced magnesium availability sensitizes cells to stimuli that activate , leading to increased release of cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), which perpetuate a cycle of chronic low-grade inflammation. Recent 2025 research has further linked this mechanism to the pathogenesis of metabolic diseases, where magnesium shortfall amplifies inflammatory responses in adipose and vascular tissues, contributing to and . Magnesium deficiency disrupts function, particularly affecting transient receptor potential melastatin (TRPM) channels responsible for magnesium influx, and altering neuronal excitability via NMDA receptors. Low extracellular magnesium reduces blockade of NMDA receptors, resulting in excessive calcium influx, hyperexcitability, and subsequent neuronal damage through . Similarly, diminished intracellular magnesium impairs TRPM6 and TRPM7 channel activity, exacerbating magnesium loss and linking to broader cellular dysfunction in epithelial and immune cells. Finally, magnesium deficiency induces by facilitating the opening of the (mPTP), a process that dissipates the mitochondrial and releases pro-apoptotic factors like . Chronic hypomagnesemia promotes mPTP sensitization through and calcium overload, shifting cells toward while supplementation can reverse this effect by stabilizing mitochondrial integrity.

Organ system effects

Magnesium deficiency exerts profound effects on multiple organ systems by disrupting balance, vascular tone, and cellular signaling pathways, often exacerbating underlying pathophysiological processes. In the cardiovascular system, hypomagnesemia promotes through enhanced calcium influx into vascular cells, leading to coronary constriction and increased risk of ischemic events. It also induces by impairing production and promoting , which contributes to arterial stiffening and . Furthermore, magnesium deficiency is associated with a higher risk of , with epidemiological studies indicating odds ratios ranging from 1.2 to 2.0 in populations with low serum magnesium levels compared to those with adequate intake. In the neurological system, magnesium deficiency heightens neuronal vulnerability to by reducing blockade of N-methyl-D-aspartate () receptors, allowing excessive glutamate-mediated calcium entry and potential neuronal damage. This mechanism underlies a predisposition to migraines, where low magnesium levels facilitate and neurogenic inflammation. Additionally, through modulation, hypomagnesemia links to depressive disorders by altering and monoaminergic signaling in key brain regions. Endocrine disruptions from magnesium deficiency include impaired insulin signaling, where low magnesium reduces insulin sensitivity by interfering with activity in insulin receptors, contributing to in . Studies suggest this effect can diminish insulin-mediated in deficient states. In pregnancy, magnesium shortfall is tied to via placental ischemia and , as hypomagnesemia promotes in uteroplacental vessels. Respiratory effects manifest as increased bronchoconstriction, with magnesium acting as a natural antagonist; its deficiency enhances calcium-dependent smooth muscle contraction in airways, worsening pathophysiology. This leads to heightened airway hyperreactivity and impaired bronchodilation. On skeletal health, magnesium deficiency hampers bone mineralization by altering secretion and metabolism, as magnesium is a cofactor in the enzymatic activation of vitamin D in the liver and kidneys to 1,25-dihydroxyvitamin D. Consequently, magnesium deficiency can impair vitamin D function, potentially leading to or compounding symptoms associated with vitamin D deficiency, such as muscle weakness, muscle cramps, fatigue (which may contribute to cognitive symptoms such as brain fog), and hair loss (including alopecia areata). This increases activity and , thereby elevating risk. Recent analyses indicate that magnesium supplementation in deficient individuals can help reduce fracture risk, highlighting its role in maintaining . A 2025 update underscores magnesium deficiency's contribution to through dysregulation of detrusor , where low magnesium promotes excessive calcium influx and involuntary contractions, increasing incidence. These organ-specific impacts often stem from broader cellular stress, including oxidative damage and ion imbalance, as detailed in molecular mechanisms.

Clinical manifestations

Neuromuscular symptoms

Magnesium deficiency, or hypomagnesemia, manifests in a range of neuromuscular symptoms primarily due to altered and muscle excitability. Common early symptoms include muscle cramps or spasms (especially nighttime leg cramps, due to impaired muscle relaxation as magnesium facilitates calcium reuptake into the sarcoplasmic reticulum for muscle relaxation), eyelid twitching, fatigue and weakness, insomnia or poor sleep quality, anxiety, irritability, low mood or depression, and cognitive symptoms such as brain fog. Common muscular complaints include cramps, spasms, and , which can range from mild discomfort to severe, involuntary contractions affecting daily activities. These symptoms often arise in moderate to severe cases and may be exacerbated by concurrent imbalances. Tremors and are frequent early signs, presenting as fine shaking or exaggerated reflexes upon clinical examination. and are also prevalent, impacting proximal and distal muscle groups and leading to generalized debility and reduced mobility. In more advanced presentations, patients may experience vertigo, , and , contributing to balance issues and coordination difficulties. Neurological involvement extends to psychiatric features such as , , and personality alterations, which can mimic other neuropsychiatric conditions. Seizures represent a severe complication, particularly in genetic forms of hypomagnesemia like hypomagnesemia with seizures and mental retardation syndrome. Positive Chvostek and Trousseau signs, indicative of neuromuscular , often occur secondary to associated . Symptoms of magnesium deficiency may overlap with those of vitamin D deficiency, including muscle weakness/cramps, fatigue (potentially contributing to brain fog), and hair loss (e.g., alopecia areata), as magnesium is essential for the activation and metabolism of vitamin D. Evidence directly linking magnesium deficiency to cold hands and feet is limited, though some sources suggest it may affect circulation, potentially contributing to cold extremities. Hypomagnesemia occurs in up to 60% of patients, and neuromuscular symptoms are common but often underrecognized in hypomagnesemic individuals.

Cardiovascular symptoms

Magnesium deficiency, or hypomagnesemia, contributes to various cardiovascular manifestations by disrupting cardiac channels and stability, leading to electrical instability in the heart. Common early symptoms include heart palpitations. One of the primary effects is the induction of arrhythmias, particularly and , which arise from prolongation of the on . Hypomagnesemia disturbs circulation, causing repolarization abnormalities that extend the QT interval and predispose to these life-threatening ventricular arrhythmias. Magnesium plays a crucial role in stabilizing cardiac cell membranes by suppressing early afterdepolarizations, and its deficiency heightens susceptibility to polymorphic . These arrhythmias are often exacerbated by concurrent imbalances, such as , as detailed in discussions of interactions. Electrocardiographic changes associated with hypomagnesemia include ST-segment depression and T-wave inversion, alongside the hallmark QT prolongation, reflecting myocardial repolarization disturbances. Early experimental studies in magnesium-deficient models demonstrated these ST and T-wave alterations, which can mimic ischemic changes and complicate . Clinically, global T-wave inversions have been observed in cases of isolated hypomagnesemia, further underscoring its impact on . Beyond arrhythmias, hypomagnesemia promotes and through intracellular accumulation of sodium and calcium, which constrict vascular and impair coronary blood flow. This contributes to ischemic heart disease, with low magnesium levels identified as a trigger for spasm-related events. Hypomagnesemia also elevates the risk of sudden cardiac , particularly in vulnerable populations such as those post-myocardial infarction, where it sensitizes the myocardium to fatal arrhythmias and increases the likelihood of adverse outcomes compared to normomagnesemic patients. Low serum magnesium serves as a predictor of sudden cardiac across cohorts, with deficiency linked to increased post-infarction mortality through mechanisms like enhanced arrhythmogenicity. Furthermore, magnesium deficiency fosters by inducing , the initial step in plaque formation, as low magnesium impairs production and promotes in vascular . In vitro and clinical evidence confirms that magnesium depletion accelerates changes and , exacerbating atherosclerotic progression. In patients with , hypomagnesemia is prevalent in 19-37% of cases and worsens symptoms by aggravating and arrhythmogenic potential, leading to poorer and increased hospitalization rates. Recent analyses from 2023 indicate that magnesium depletion correlates with higher cardiovascular event rates.

Other systemic effects

Magnesium deficiency, or hypomagnesemia, manifests in various gastrointestinal disturbances due to impaired smooth muscle function and overall metabolic disruption in the digestive tract. Early symptoms often include headaches, anorexia, characterized by a significant loss of appetite, alongside nausea, vomiting, and constipation or other digestive issues, which can exacerbate nutritional deficits and contribute to a cycle of further magnesium depletion. Constipation is another common feature, arising from reduced peristalsis and poor relaxation of intestinal smooth muscles, as magnesium plays a critical role in modulating calcium-dependent contractions; deficiency leads to diminished motility and harder stools. In metabolic contexts, hypomagnesemia is associated with and poor glycemic control in individuals with , where low magnesium impairs insulin signaling and glucose . General symptoms like profound also emerge, reflecting magnesium's essential role in energy metabolism and neurotransmitter regulation; low levels disrupt ATP production and GABA activity, resulting in persistent tiredness. Ocular manifestations may involve , such as vertical or downbeat types, though these are less frequent and often reversible with correction of magnesium levels. In pediatric cases, particularly those involving congenital magnesium-wasting disorders like , chronic hypomagnesemia can lead to growth retardation and , with affected children exhibiting stunted linear growth and delayed weight gain due to persistent metabolic and nutritional impairments if untreated.

Diagnosis

Laboratory evaluation

Laboratory evaluation of magnesium deficiency, also known as hypomagnesemia, primarily relies on biochemical tests to assess magnesium status, though these have inherent limitations in reflecting total body stores. Serum magnesium measurement serves as the initial and most common test, with normal levels typically ranging from 0.73 to 1.06 mmol/L (1.8 to 2.6 mg/dL). Hypomagnesemia is generally defined as a serum level below 0.7 mmol/L (1.7 mg/dL), with mild deficiency at 0.5–0.7 mmol/L, moderate at 0.4–0.5 mmol/L, and severe below 0.4 mmol/L (1.0 mg/dL); definitions vary slightly across sources. However, serum magnesium reflects only about 1% of total body magnesium, which is predominantly intracellular, leading to low sensitivity for detecting mild or early deficiency where levels may remain normal despite depleted stores. Urinary magnesium assessment helps differentiate causes of deficiency, particularly renal versus extrarenal losses. A 24-hour urine collection showing excretion greater than 10-30 mg (0.4-1.2 mmol) suggests renal wasting, while lower levels indicate extrarenal causes such as gastrointestinal losses. Alternatively, fractional excretion of magnesium (FEMg), calculated from a spot urine sample as [(urine Mg × plasma creatinine) / (0.7 × plasma Mg × urine creatinine)] × 100, is useful; a value greater than 2-4% indicates renal magnesium loss, whereas less than 2% points to appropriate renal conservation in deficiency. Other markers provide a more accurate gauge of intracellular magnesium. (RBC) magnesium measures intracellular levels, offering higher sensitivity than serum for chronic deficiency, though it is not standardized for routine clinical use and is mainly employed in settings. Ionized magnesium, the free and biologically active form, can be measured using ion-selective electrodes and may better reflect physiological status, but its clinical utility remains unproven compared to total serum magnesium and is not routinely recommended. Associated laboratory tests are essential due to magnesium's interactions with other electrolytes. Serum potassium and calcium levels should be evaluated, as hypomagnesemia often coexists with and , complicating correction without addressing magnesium first. (PTH) measurement is also relevant, as low magnesium impairs PTH secretion and action, contributing to secondary hypocalcemia. Diagnostic challenges arise in distinguishing acute from chronic deficiency, as serum levels may normalize quickly with redistribution while intracellular depletion persists, necessitating serial testing or loading studies in ambiguous cases. Overall, no single test perfectly captures total body magnesium, highlighting the need for clinical correlation.

Clinical and instrumental assessment

Symptoms of magnesium deficiency overlap with those of other conditions, so accurate confirmation requires professional evaluation via laboratory testing; self-diagnosis and self-treatment are not recommended, and consultation with a healthcare provider is advised if deficiency is suspected. Clinical assessment of magnesium deficiency begins with a thorough history to identify risk factors and symptoms suggestive of hypomagnesemia. Key elements include evaluating dietary habits, such as low intake of magnesium-rich foods like nuts, seeds, and leafy greens, which can contribute to subclinical deficiency. History should also probe use, particularly inhibitors, diuretics, and aminoglycosides, which impair magnesium absorption or increase renal . Gastrointestinal symptoms like chronic diarrhea or syndromes, and renal issues such as , further heighten suspicion. To aid risk stratification, validated questionnaires like the Magnesium Deficiency Questionnaire (MDQ) can be employed; the MDQ-23, for instance, assesses symptoms across , , and categories, with scores above 9 indicating potential deficiency when serum magnesium is below 0.8 mmol/L. Physical examination focuses on signs of neuromuscular irritability, which arise from magnesium's role in stabilizing neuronal membranes. Trousseau's sign, elicited by inflating a cuff above systolic pressure for up to 3 minutes to induce carpopedal , reflects hyperexcitability and is positive in severe cases, often alongside associated . Muscle strength testing may reveal weakness or tremors, while generalized fasciculations or can occur in advanced deficiency. Chvostek's sign, involving facial twitching upon tapping the , may also be present, though less specific. These findings, while not , guide the need for further evaluation when combined with history. Electrocardiographic (ECG) assessment is instrumental in detecting cardiovascular involvement, as hypomagnesemia disrupts cardiac . Prolonged , typically exceeding 440 ms, is a common finding and predisposes to ventricular arrhythmias like . Prominent U waves and ST-T wave abnormalities, such as flattening or inversion, further indicate . These changes are reversible with correction but necessitate prompt recognition, especially in patients with syncope or . ECG thus complements clinical suspicion, though interpretation should integrate with laboratory confirmation of serum magnesium levels. Imaging modalities are rarely indicated for routine magnesium deficiency assessment but play a role in suspected genetic etiologies. In familial hypomagnesemia with and (FHHNC), renal may reveal bilateral , characterized by hyperechoic medullary deposits due to chronic and magnesium wasting. This finding supports genetic diagnosis in pediatric or young adult patients with refractory hypomagnesemia and renal impairment; confirmatory identifies mutations in genes such as CLDN16 or CLDN19, guiding . The magnesium loading test provides a functional measure of total body magnesium stores, particularly when serum levels are normal but deficiency is suspected. This involves intravenous administration of 30 mmol of magnesium sulfate over 8-12 hours, followed by 24-hour urine collection to quantify excretion. Retention greater than 30% of the administered dose (or urinary excretion less than 70%)—with thresholds varying by study (e.g., >27.5% or >45% indicating deficiency)—suggests intracellular deficiency, as the body avidly retains magnesium to replete stores. This test is especially useful in chronic conditions like or but requires careful monitoring to avoid .

Management

Dietary and oral supplementation

Dietary management of magnesium deficiency primarily involves increasing intake of magnesium-rich foods to meet or exceed the recommended dietary allowance (RDA), which is approximately 310–420 mg per day for adults depending on age and . Foods such as leafy green vegetables and nuts are particularly effective sources; for example, boiled provides about 80 mg of magnesium per 100 g, while almonds offer around 270 mg per 100 g. Incorporating a variety of these into daily meals—such as adding to salads or snacking on almonds—can help restore magnesium levels in mild cases without the need for supplements. Oral supplementation is recommended for individuals with confirmed mild magnesium deficiency, typically when dietary changes alone are insufficient. Common forms include , which has low of about 4%, and , with higher absorption rates up to 30%. Dosing generally ranges from 200–400 mg of magnesium daily, taken in divided doses to enhance absorption and minimize gastrointestinal upset. These supplements should be chosen based on and individual tolerance, with citrate often preferred for its better uptake. Monitoring is essential during oral supplementation, particularly for mild hypomagnesemia defined by serum magnesium levels of 0.5–0.7 mmol/L. Regular serum testing can track progress toward normalization (typically 0.75–0.95 mmol/L), with adjustments made if levels do not improve after 1–3 months. Side effects, such as , are common at doses exceeding 350 mg of supplemental magnesium per day and may necessitate dose reduction or switching forms. In special populations like pregnant women, oral magnesium supplementation of 350 mg per day is advised to support and potentially prevent , especially in high-risk cases. A 2025 meta-analysis of randomized controlled trials found that such supplementation significantly reduced risk ( 0.76). Evidence from recent supports the efficacy of dietary and oral magnesium interventions for symptom improvement in magnesium deficiency. A 2023 and of randomized trials demonstrated significant reductions in depression symptoms with oral magnesium supplementation. Similarly, a 2024 study reported notable enhancements in quality and mood following magnesium supplementation compared to . In individuals with hypertension, particularly those with magnesium deficiency, doses of approximately 300–400 mg/day have been shown to reduce systolic blood pressure (SBP) by 2–4 mmHg (e.g., 2–2.8 mmHg overall, up to 4.18 mmHg) and diastolic blood pressure (DBP) by 1–2 mmHg, with greater effects in deficient states; food sources are preferred where possible. Additionally, in patients with diabetic nephropathy—a condition often associated with magnesium deficiency due to renal wasting—oral magnesium supplementation has been shown to reduce proteinuria. A 2023 prospective randomized controlled trial found that magnesium citrate supplementation (equivalent to 360 mg elemental magnesium daily) significantly reduced the urinary albumin-to-creatinine ratio (median percent reduction -6.87% vs -0.9% in controls, p=0.001) and improved estimated glomerular filtration rate. These findings underscore the value of non-invasive approaches for mild to moderate deficiency.

Intravenous and advanced therapies

Intravenous is the primary intervention for severe or symptomatic hypomagnesemia, particularly when rapid correction is required to prevent life-threatening complications such as ventricular arrhythmias or seizures. Indications include symptomatic cases (e.g., , arrhythmias), serum magnesium levels below 0.5 mmol/L, or situations complicated by renal impairment where oral absorption is unreliable. For acute hypomagnesemia, an initial bolus of 1-2 g of is administered intravenously over 1-2 hours, with repeat doses as needed based on clinical response and serial monitoring. Maintenance infusions typically range from 4-6 g per day, adjusted to achieve normalization while avoiding toxicity, with total body deficits estimated at 0.5-1.0 mmol/kg in severe cases. According to ASPEN guidelines, repletion should be tailored to severity, renal function, and concomitant abnormalities. During therapy, close monitoring of serum magnesium levels, electrocardiograms (ECG), and renal function is essential to detect potential complications like , which can cause respiratory depression when levels exceed 2 mmol/L. Post-infusion targets generally aim for serum levels of 0.8-1.0 mmol/L to restore , though equilibration between serum and intracellular compartments may take hours, necessitating repeated assessments. Concomitant repletion of associated electrolytes, such as and calcium, is often required due to interdependent deficiencies commonly observed in hypomagnesemia. In patients with renal failure, advanced therapies like may be employed to remove excess magnesium if develops, while continuing cautious IV dosing under dialysis guidance. Evidence from (ICU) trials supports the use of IV magnesium in critically ill patients with hypomagnesemia, demonstrating a significant reduction in in-hospital mortality ( 0.71; 95% CI 0.59-0.85) compared to untreated cases, particularly in conditions like . These findings underscore the prognostic benefits of prompt correction, though prospective studies are needed to refine protocols.

Epidemiology and risk groups

Global prevalence

Magnesium deficiency, also known as hypomagnesemia, affects an estimated 2.5% to 15% of the general when assessed via serum magnesium levels. In hospitalized and (ICU) patients, prevalence is substantially higher, ranging from 20% to 65%, often exacerbated by critical illness, imbalances, and medical interventions. Regional variations in magnesium deficiency are influenced by soil quality, dietary patterns, and agricultural practices. In , approximately 55% of arable lands exhibit magnesium-deficient soils (exchangeable magnesium <120 mg kg⁻¹), contributing to reduced magnesium content in crops and higher dietary shortfalls. Approximately 48% of adults consume less than the estimated average requirement (EAR) for magnesium from , with similar trends observed in European populations where intakes often fall below recommended levels due to reliance on processed and refined foods. In developing regions like parts of , dietary magnesium deficiency risk was low at under 4% based on 2007 food supply data, though access limitations and soil variability can elevate concerns in specific areas. Trends indicate a rising global burden of magnesium deficiency, driven by the increasing consumption of processed foods that are low in magnesium and high in refining agents like phosphates and sugars, which impair absorption. In the elderly, and age-related factors have contributed to heightened prevalence, with studies linking multiple medications to magnesium depletion and cognitive risks. Subclinical magnesium deficiency, a principal driver of and a crisis, may affect up to 10-30% of the general globally, with higher rates in developed due to dietary patterns. Assessing true magnesium deficiency poses challenges, as serum magnesium measurements— the most common method—often underestimate , reflecting only 1% of total body magnesium and missing intracellular deficits. (RBC) magnesium testing provides a more accurate gauge of tissue stores, revealing deficiencies in up to 50% of cases where serum levels appear normal.

At-risk populations

Certain demographic and clinical groups exhibit heightened susceptibility to magnesium deficiency due to physiological, lifestyle, or environmental factors. The elderly population is particularly vulnerable, with prevalence rates estimated at 20-30% in unselected older adults, primarily attributable to diminished gastrointestinal absorption, (e.g., diuretics and inhibitors), and inadequate dietary intake. Individuals with chronic diseases face elevated risks, as underlying conditions exacerbate magnesium losses or impair . In patients with , hypomagnesemia prevalence ranges from 25-40%, linked to and renal wasting that further deplete magnesium stores. Chronic alcoholics experience deficiencies in 30-60% of cases, driven by poor nutrition, gastrointestinal , and alcohol-induced renal . Critically ill patients in intensive care settings show hypomagnesemia in up to 50-65% of admissions, often due to stress responses, fluid shifts, and therapeutic interventions like . Pregnant women have increased magnesium requirements to support fetal development and maternal homeostasis, with deficiency implicated in complications such as pre-eclampsia; meta-analyses of supplementation trials indicate a modest risk reduction of approximately 8-24% in pre-eclampsia incidence, particularly in high-risk cohorts. Athletes, especially those in endurance or high-intensity sports, are prone to depletion from sweat losses averaging 10-20 mg of magnesium per liter, potentially elevating requirements by 10-20% above baseline; a 2025 national survey analysis further highlighted magnesium depletion as a risk factor for urinary incontinence prevalence in women, including athletic populations. Socioeconomic factors compound vulnerability in low-income groups, where access to magnesium-rich foods like nuts, seeds, and whole grains is limited by reliance on nutrient-poor, processed diets, contributing to subclinical deficiencies across affected communities.

Historical context

Early recognition

The initial recognition of magnesium deficiency in humans emerged from animal studies and early clinical observations in the early . In the 1930s, researchers at , led by E.V. McCollum, demonstrated that magnesium is an essential nutrient through experiments on rats and dogs fed magnesium-deprived diets, which induced symptoms such as , , and growth failure; these findings were extrapolated to , establishing magnesium's vital role beyond calcium and in and muscle function. Human cases were first documented in 1934 by Arthur D. Hirschfelder and Victor G. Haury, who reported markedly low serum magnesium levels (as low as 0.8 mEq/L) in patients with tetany-like symptoms, particularly those with undergoing Epsom salt () purgation, highlighting the risks of iatrogenic hypomagnesemia and its association with neuromuscular irritability. This built on veterinary observations from the late 1920s, where magnesium supplementation resolved in , but marked the shift to . Following , in the 1940s, studies on among war survivors and prisoners revealed imbalances, including hypomagnesemia, during refeeding efforts, underscoring magnesium's importance in preventing complications like in starved individuals. By the early 1950s, magnesium deficiency gained further attention in clinical settings; Edmund B. Flink identified chronic hypomagnesemia in alcoholics with , linking poor intake, gastrointestinal losses, and renal wasting to symptoms such as tremors and seizures. Concurrently, observations in intensive care units during the 1950s connected low magnesium to cardiac arrhythmias, with parenteral showing efficacy in suppressing ventricular ectopy and in critically ill patients. These developments laid the groundwork for later therapeutic advances.

Key advancements

In the , intravenous emerged as a frontline for when combined with antihypertensive medications and delivery, marking a significant shift in managing severe preeclampsia-eclampsia cases in the United States. This approach built on earlier intramuscular uses from the early 1900s but gained widespread adoption due to its demonstrated anticonvulsant effects, reducing maternal mortality risks associated with . Subsequent National Institutes of Health-supported trials in the 1980s further confirmed its efficacy, showing intravenous significantly lowered recurrent rates compared to alternatives like , solidifying its as the . During the 1980s and 1990s, genetic research advanced understanding of inherited forms of magnesium deficiency, with the 1996 identification of mutations in the SLC12A3 gene as the primary cause of , a salt-losing tubulopathy characterized by hypokalemic and chronic hypomagnesemia. This discovery distinguished from related disorders like and highlighted the role of renal tubular defects in magnesium , enabling targeted genetic diagnostics. In the , the association between proton pump inhibitors (PPIs) and hypomagnesemia was established through case reports and mechanistic studies, revealing that long-term PPI use impairs intestinal magnesium absorption via downregulation of transient receptor potential melastatin 6 and 7 channels. This link prompted the U.S. Food and Drug Administration to issue a 2011 safety warning, advising monitoring of serum magnesium levels in patients on prolonged PPI therapy (typically over one year), as hypomagnesemia could lead to serious cardiac arrhythmias and seizures. The 2000s also saw epidemiological insights from the linking low magnesium intake to components of , including and , with higher dietary magnesium associated with a reduced of these factors for and . This underscored magnesium's protective role against and in metabolic disorders. In the 2020s, research has deepened the connection between magnesium deficiency and , with 2024 studies demonstrating that hypomagnesemia exacerbates production through mitochondrial dysfunction and disrupted , contributing to cellular damage in conditions like neurodegeneration and metabolic diseases. Concurrently, 2024-2025 investigations have identified magnesium depletion as a risk factor for , particularly , via analyses showing higher magnesium depletion scores correlate with increased prevalence and severity due to impaired function and signaling. Meta-analyses from this period have further evidenced cardiovascular benefits of supplementation, with 2025 reviews indicating that doses of 300-400 mg/day reduce systolic and diastolic by 2-4 mmHg in hypertensive individuals and lower risk by up to 20% in those with , highlighting magnesium's role in endothelial protection and prevention.

Applications in plants

Manifestations in plants

Magnesium deficiency in plants typically presents as interveinal , characterized by yellowing of the leaf tissue between the veins while the veins themselves remain green, primarily affecting older leaves. This symptom arises because magnesium serves as the central atom in the molecule, which is essential for and gives leaves their green color; a deficiency disrupts synthesis, leading to reduced photosynthetic capacity. In common crops such as corn and tomatoes, early signs appear on lower leaves as bright yellow interveinal areas, often with a reddish-purple or violet tinge in advanced stages, progressing to tip burn, edge , and overall stunted growth. Similar patterns occur in soybeans and cucurbits, where the starts on mature foliage and can reduce vigor, though growth may initially appear normal. Eggplants exhibit similar manifestations of magnesium deficiency, with yellowing between the veins (interveinal chlorosis) on leaves, veins remaining green, typically starting on older leaves and potentially progressing to younger leaves or leading to necrosis in severe cases. For woody ornamentals and trees, manifestations include broad interveinal or marginal on older leaves, sometimes appearing as mottled patterns, without immediate but potentially leading to premature drop and weakened branches. relies on tissue analysis, where magnesium levels below 0.2% in dry matter indicate deficiency, and tests showing exchangeable magnesium under 50-60 ppm in the confirm low availability, particularly in acidic or sandy soils.

Agricultural implications

Magnesium deficiency in agricultural crops arises primarily from soil-related factors that limit the availability of this essential nutrient to plants. Acidic soils with a pH below 5.5 reduce magnesium solubility and uptake, as low pH increases the solubility of aluminum and other ions that compete with magnesium for root absorption. High levels of potassium (K) and calcium (Ca) in the soil exacerbate the issue through cation competition, where these abundant ions displace magnesium from soil exchange sites and root uptake mechanisms. Additionally, magnesium is highly susceptible to leaching in sandy or low-cation-exchange-capacity soils, particularly during heavy rainfall or irrigation, leading to rapid nutrient loss from the root zone. Prevention strategies focus on soil amendments and targeted applications to maintain adequate magnesium levels. Applying dolomitic lime, which contains magnesium (MgCO₃), effectively raises while supplying magnesium, especially in acidic fields; rates are typically based on recommendations to achieve a target of 6.0-7.0. Foliar sprays of (MgSO₄) at concentrations of 1-2% provide rapid correction for acute deficiencies, with applications of 10-20 pounds of MgSO₄ per acre in 20-30 gallons of per acre often sufficient for and field crops. Soil fertilization with magnesium sources such as potassium-magnesium sulfate or langbeinite at rates of 20-50 kg Mg per can sustain levels in deficient soils, particularly for high-demand crops like corn and , and should be integrated with overall plans. The economic impacts of magnesium deficiency are significant, as it directly reduces crop yields and quality in affected regions. In magnesium-poor soils, yield losses can reach 5-10%, with severe deficiencies causing up to 9.4% reductions in grain crops like and corn; for instance, a of international field studies highlights similar productivity declines due to widespread limitations. These losses compound global food security challenges, as magnesium deficiency affects approximately 90-98% of agricultural s worldwide, particularly in intensively farmed areas with sandy or leached profiles. Soil testing protocols are essential for early detection and management of magnesium deficiency in agriculture. The Mehlich-3 extractant is widely used to measure extractable magnesium levels, providing a reliable index of plant-available Mg in acidic to neutral soils; critical thresholds are typically below 60 ppm, depending on crop type and soil properties. Integrating these tests into sustainable farming practices, such as and , allows farmers to apply magnesium amendments proactively, minimizing environmental impacts like nutrient runoff while optimizing use efficiency.

References

  1. https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/
  2. https://www.ncbi.nlm.nih.gov/books/NBK500003/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC6024559/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC12566843/
  5. https://medlineplus.gov/ency/article/000315.htm
  6. https://emedicine.medscape.com/article/2038394-overview
  7. https://www.merriam-webster.com/dictionary/hypomagnesemia
  8. https://www.mountsinai.org/health-library/diseases-conditions/low-magnesium-level
  9. https://emedicine.medscape.com/article/2038394-workup
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC5926493/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC4455825/
  12. https://www.ncbi.nlm.nih.gov/books/NBK519036/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC3681045/
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC5652077/
  15. https://pubmed.ncbi.nlm.nih.gov/14576148/
  16. https://nutritionsource.hsph.harvard.edu/magnesium/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC1855626/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC6873028/
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC8729834/
  20. https://pubmed.ncbi.nlm.nih.gov/9513927/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC6746263/
  22. https://australianprescriber.tg.org.au/articles/magnesium-the-forgotten-electrolyte.html
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC4007268/
  24. https://turkjnephrol.org/Content/files/sayilar/329/96-97%281%29.pdf
  25. https://pubmed.ncbi.nlm.nih.gov/29796601/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC10722944/
  27. https://link.springer.com/article/10.1007/s12011-024-04368-1
  28. https://www.ncbi.nlm.nih.gov/books/NBK549880/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC8229336/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC4482822/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC2658800/
  32. https://royalsocietypublishing.org/doi/10.1098/rsos.231484
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC6946416/
  34. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-low-magnesium-levels-can-be-associated-long-term-use-proton-pump
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC5872533/
  36. https://emcrit.org/ibcc/hypophos/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC5440500/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC3338284/
  39. https://pubmed.ncbi.nlm.nih.gov/33595712/
  40. https://www.orpha.net/en/disease/detail/306516
  41. https://www.ncbi.nlm.nih.gov/books/NBK459304/
  42. https://www.nature.com/articles/s41598-021-95521-6
  43. https://www.nature.com/articles/ejhg2013178
  44. https://omim.org/entry/602014
  45. https://www.nejm.org/doi/full/10.1056/NEJMoa0810276
  46. https://www.orpha.net/en/disease/detail/199343
  47. https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1001045
  48. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239965
  49. https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2025.1600877/full
  50. https://www.nature.com/articles/s41467-023-43400-1
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC12222124/
  52. https://lpi.oregonstate.edu/mic/minerals/magnesium
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC10385004/
  54. https://www.mdpi.com/2072-6643/13/4/1136
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC5112180/
  56. https://pubmed.ncbi.nlm.nih.gov/27854048/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC5783146/
  58. https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-025-01772-y
  59. https://www.ncbi.nlm.nih.gov/books/NBK507254/
  60. https://www.mdpi.com/2072-6643/15/18/3920
  61. https://pubmed.ncbi.nlm.nih.gov/35063139/
  62. https://www.sciencedirect.com/science/article/pii/S1347861321001171
  63. https://pubmed.ncbi.nlm.nih.gov/7361117/
  64. https://www.mdpi.com/1422-0067/19/6/1724
  65. https://nutritionj.biomedcentral.com/articles/10.1186/s12937-017-0247-4
  66. https://www.sciencedirect.com/science/article/pii/S0753332218312058
  67. https://msu-journal.com/index.php/journal/article/view/72
  68. https://diabetesjournals.org/care/article/28/5/1175/27632/Magnesium-Deficiency-Is-Associated-With-Insulin
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC6470576/
  70. https://www.ahajournals.org/doi/10.1161/01.HYP.0000137592.76535.8c
  71. https://www.sciencedirect.com/science/article/abs/pii/000282239391675G
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC5968247/
  73. https://pubmed.ncbi.nlm.nih.gov/29480918/
  74. https://my.clevelandclinic.org/health/diseases/15050-vitamin-d-vitamin-d-deficiency
  75. https://www.healthline.com/nutrition/vitamin-d-deficiency-symptoms
  76. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1406248/full
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC8313472/
  78. https://www.nature.com/articles/s41598-025-17962-7
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC10745813/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC4062555/
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC11508242/
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC10272912/
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC9064401/
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC5417264/
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC9000947/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC5474543/
  87. https://my.clevelandclinic.org/health/diseases/23264-hypomagnesemia
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC10547470/
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC9598104/
  90. https://emedicine.medscape.com/article/1950863-overview
  91. https://litfl.com/hypomagnesaemia-ecg-library/
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC7873644/
  93. https://www.sciencedirect.com/science/article/abs/pii/S0736467913004538
  94. https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2020.608193/full
  95. https://onlinelibrary.wiley.com/doi/10.1155/2019/4874921
  96. https://openheart.bmj.com/content/5/2/e000775
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC2939007/
  98. https://portlandpress.com/clinsci/article/122/9/397/68973/Endothelial-cells-and-magnesium-implications-in
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC6032400/
  100. https://www.sciencedirect.com/science/article/pii/S0953620524004448
  101. https://www.ahajournals.org/doi/10.1161/JAHA.123.030077
  102. https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/electrolyte-disorders/hypomagnesemia
  103. https://pmc.ncbi.nlm.nih.gov/articles/PMC11969968/
  104. https://www.ncbi.nlm.nih.gov/books/NBK507250/
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC5572672/
  106. https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2021.544925/full
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC10693313/
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC7400907/
  109. https://pmc.ncbi.nlm.nih.gov/articles/PMC6524065/
  110. https://pubmed.ncbi.nlm.nih.gov/15856319/
  111. https://omim.org/entry/248250
  112. https://pubmed.ncbi.nlm.nih.gov/8171268/
  113. https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2796.1999.00580.x
  114. https://www.goodrx.com/well-being/diet-nutrition/foods-high-in-magnesium
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC6683096/
  116. https://www.drugs.com/article/magnesium.html
  117. https://www.verywellhealth.com/types-of-magnesium-what-they-are-and-how-to-choose-8748803
  118. https://mcpress.mayoclinic.org/living-well/magnesium-are-you-low-but-dont-know/
  119. https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-020-02877-0
  120. https://www.nature.com/articles/s41440-025-02144-9
  121. https://pmc.ncbi.nlm.nih.gov/articles/PMC10783196/
  122. https://esmed.org/MRA/mra/article/view/5410
  123. https://pubmed.ncbi.nlm.nih.gov/27402922/
  124. https://www.ajkd.org/article/S0272-6386(23)01002-8/fulltext
  125. https://emedicine.medscape.com/article/2038394-treatment
  126. https://emcrit.org/ibcc/hypomagnesemia/
  127. https://www.ncbi.nlm.nih.gov/books/NBK562314/
  128. https://www.nature.com/articles/s41598-025-19526-1
  129. https://jintensivecare.biomedcentral.com/articles/10.1186/s40560-018-0291-y
  130. https://pmc.ncbi.nlm.nih.gov/articles/PMC12388162/
  131. https://pmc.ncbi.nlm.nih.gov/articles/PMC9085447/
  132. https://www.gov.uk/research-for-development-outputs/risk-of-dietary-magnesium-deficiency-is-low-in-most-african-countries-based-on-food-supply-data
  133. https://pmc.ncbi.nlm.nih.gov/articles/PMC7649274/
  134. https://www.pharmacytimes.com/view/study-half-of-all-americans-are-magnesium-deficient
  135. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1646741/full
  136. https://pmc.ncbi.nlm.nih.gov/articles/PMC12537121/
  137. https://pmc.ncbi.nlm.nih.gov/articles/PMC5786912/
  138. https://pmc.ncbi.nlm.nih.gov/articles/PMC6316205/
  139. https://www.droracle.ai/articles/353965/how-common-is-magnesium-deficiency
  140. https://medlineplus.gov/lab-tests/magnesium-blood-test/
  141. https://alliedhealth.ceconnection.com/files/MagnesiumDeficiencyWhatIsOurStatus-1465322240653.pdf
  142. https://diabetesjournals.org/diabetes/article/65/1/3/34908/Hypomagnesemia-in-Type-2-Diabetes-A-Vicious-Circle
  143. https://brieflands.com/journals/ijem/articles/17676
  144. https://archivesbiologicalpsychiatry.org/the-importance-of-monitoring-magnesium-levels-in-alcohol-withdrawal-delirium
  145. https://www.jocmr.org/index.php/JOCMR/article/download/2351/1287
  146. https://pmc.ncbi.nlm.nih.gov/articles/PMC10426318/
  147. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1439134/full
  148. https://bfesse.com/sport-nutrition-cmo/magnesium-types-hydration-formulas
  149. https://pubmed.ncbi.nlm.nih.gov/17172008/
  150. https://pubmed.ncbi.nlm.nih.gov/40370795/
  151. https://journals.physiology.org/doi/full/10.1152/ajplegacy.1932.101.3.454
  152. https://jamanetwork.com/journals/jama/fullarticle/249185
  153. https://pmc.ncbi.nlm.nih.gov/articles/PMC1500911/
  154. https://pmc.ncbi.nlm.nih.gov/articles/PMC11065092/
  155. https://pubmed.ncbi.nlm.nih.gov/13130933/
  156. https://pubmed.ncbi.nlm.nih.gov/15413579/
  157. https://mdedge.com/obgyn/article/61372/judicious-use-magnesium-sulfate-eclampsia
  158. https://www.preeclampsia.org/the-news/health-information/history-of-preeclampsia
  159. https://pmc.ncbi.nlm.nih.gov/articles/PMC6816808/
  160. https://pmc.ncbi.nlm.nih.gov/articles/PMC2843570/
  161. https://link.springer.com/article/10.1007/s004670050158
  162. https://pmc.ncbi.nlm.nih.gov/articles/PMC3782221/
  163. https://www.ahajournals.org/doi/10.1161/circulationaha.105.588847
  164. https://www.sciencedirect.com/science/article/abs/pii/S0899900715004062
  165. https://pmc.ncbi.nlm.nih.gov/articles/PMC11351329/
  166. https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.125.25129
  167. https://www.ahajournals.org/doi/10.1161/JAHA.124.038870
  168. https://extension.sdstate.edu/monitoring-and-correcting-magnesium-deficiency-high-tunnels
  169. https://plant-pest-advisory.rutgers.edu/magnesium-deficiency-in-tomato/
  170. https://veggiescout.mgcafe.uky.edu/magnesium-deficiency-cucurbit-crops
  171. https://edis.ifas.ufl.edu/publication/SS582
  172. https://soiltesting.cahnr.uconn.edu/a-primer-on-plant-nutrition/
  173. https://www.canr.msu.edu/news/magnesium_deficiency_issues_in_michigan_corn_fields
  174. https://plantscience.psu.edu/research/labs/roots/methods/methods-info/nutritional-disorders-displayed/magnesium-deficiency
  175. https://content.ces.ncsu.edu/mid-season-soybean-magnesium-deficiency
  176. https://www.vegetables.bayer.com/gb/en-uk/knowledge-centre/disease-guides/pepper-eggplant/nutrient-disorders.html
  177. https://edis.ifas.ufl.edu/publication/EP362
  178. https://extension.umd.edu/resource/fertilizing-trees-and-shrubs-and-nutrient-deficiency-symptoms
  179. https://edis.ifas.ufl.edu/publication/EP081
  180. https://corn.aae.wisc.edu/Management/pdfs/a2524.pdf
  181. https://extension.umn.edu/micro-and-secondary-macronutrients/magnesium-crop-production
  182. http://nmsp.cals.cornell.edu/publications/factsheets/factsheet59.pdf
  183. https://content.ces.ncsu.edu/pdf/fertilizer-use/2024-02-14/05_ve_Chapter_4.pdf
  184. https://www.canr.msu.edu/resources/secondary_and_micro_nutrients_for_vegetable_and_field_crops_e486
  185. https://pmc.ncbi.nlm.nih.gov/articles/PMC9573643/
  186. https://pmc.ncbi.nlm.nih.gov/articles/PMC6992656/
  187. https://www.mdpi.com/1422-0067/22/4/1819
  188. https://www.canr.msu.edu/resources/understanding_the_msu_soil_test_report_e0015
  189. https://edis.ifas.ufl.edu/publication/SS620
Add your contribution
Related Hubs
User Avatar
No comments yet.